Online citations, reference lists, and bibliographies.
← Back to Search

Involvement Of Proteasome α-Subunit PSMA7 In Hepatitis C Virus Internal Ribosome Entry Site-Mediated Translation

M. Krueger, C. Beger, P. J. Welch, J. Barber, M. Manns, F. Wong-Staal
Published 2001 · Biology

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Ribozymes are small catalytic RNA molecules that can be engineered to enzymatically cleave RNA transcripts in a sequence-specific fashion and thereby inhibit expression and function of the corresponding gene product. With their simple structures and site-specific cleavage activity, they have been exploited as potential therapeutic agents in a variety of human disorders, including hepatitis C virus (HCV) infection. We have designed a hairpin ribozyme (Rz3′X) targeting the HCV minus-strand replication intermediate at position 40 within the 3′X tail. Surprisingly, Rz3′X was found to induce ganciclovir (GCV)-resistant colonies in a bicistronic cellular reporter system with HCV internal ribosome entry site (IRES)-dependent translation of herpes simplex virus thymidine kinase (TK). Rz3′X-transduced GCV-resistant HeLa reporter cells showed substantially reduced IRES-mediated HCV core protein translation compared with control vector-transduced cells. Since these reporter systems do not contain the HCV 3′X tail sequences, the results indicate that Rz3′X probably exerted an inhibitory effect on HCV IRES activity fortuitously through another gene target. A novel technique of ribozyme cleavage-based target gene identification (cleavage-specific amplification of cDNA ends) (M. Krüger, C. Beger, P. J. Welch, J. R. Barber, and F. Wong-Staal, Nucleic Acids Res. 29:e94, 2001) revealed that human 20S proteasome α-subunit PSMA7 mRNA was a target RNA recognized and cleaved by Rz3′X. We then showed that additional ribozymes directed against PSMA7 RNA inhibited HCV IRES activity in two assay systems: GCV resistance in the HeLa IRES TK reporter cell system and a transient transfection assay performed with a bicistronicRenilla-HCV IRES-firefly luciferase reporter in Huh7 cells. In contrast, ribozymes were inactive against IRES of encephalomyocarditis virus and human rhinovirus. Additionally, proteasome inhibitor MG132 exerted a dose-dependent inhibitory effect on HCV IRES-mediated translation but not on cap-dependent translation. These data suggest a principal role for PSMA7 in regulating HCV IRES activity, a function essential for HCV replication.
This paper references
10.1073/PNAS.98.1.130
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.
C. Beger (2001)
10.1126/SCIENCE.290.5498.1972
Efficient initiation of HCV RNA replication in cell culture.
K. J. Blight (2000)
10.1128/JVI.70.5.3307-3312.1996
Structure of the 3' terminus of the hepatitis C virus genome.
T. Tanaka (1996)
10.1038/357375A0
Proteolysis, proteasomes and antigen presentation
A. Goldberg (1992)
10.1006/GENO.2000.6230
Identification and validation of a gene involved in anchorage-independent cell growth control using a library of randomized hairpin ribozymes.
P. Welch (2000)
10.1038/sj.cdd.4400384
Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration
K. Lin (1998)
Ribozymes in cancer gene therapy, p. 139–152
C. Beger (1998)
10.1016/S0140-6736(97)90013-1
Gene therapy of cancer
R. Weichselbaum (1997)
10.1128/JVI.70.8.5582-5591.1996
Proteasome complex as a potential cellular target of hepatitis B virus X protein.
J. Huang (1996)
10.1093/nar/28.13.2605
A novel functional genomics approach identifies mTERT as a suppressor of fibroblast transformation
Q. Li (2000)
10.1016/S0958-1669(98)80034-7
Expression of ribozymes in gene transfer systems to modulate target RNA levels.
P. J. Welch (1998)
10.1128/JVI.72.5.3845-3850.1998
Antiviral Activity of the Proteasome on Incoming Human Immunodeficiency Virus Type 1
O. Schwartz (1998)
10.1126/SCIENCE.285.5424.110
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.
V. Lohmann (1999)
10.1016/S0076-6879(99)06014-0
Use of ribozymes to inhibit gene expression.
M. Krueger (1999)
10.1073/PNAS.94.7.2939
Subunit arrangement in the human 20S proteasome.
F. Kopp (1997)
10.1016/S0378-1119(99)00334-0
Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function.
A. R. Muotri (1999)
10.1128/JVI.74.4.2046-2051.2000
Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo
A. A. Kolykhalov (2000)
10.1038/sj.gt.3300441
Intracellular application of hairpin ribozyme genes against hepatitis B virus
P. Welch (1997)
10.1016/b978-012437551-2/50006-9
Ribozymes in Cancer Gene Therapy
C. Beger (2002)
10.1128/JVI.70.6.3363-3371.1996
Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA.
A. A. Kolykhalov (1996)
10.1016/S0168-8278(01)81344-1
C-SPACE (cleavage-specific amplification of cDNA ends): a novel method of ribozyme-mediated gene identification.
M. Krueger (2001)
10.1093/NAR/29.19.E94
C-SPACE (cleavage-specific amplification of cDNA ends): a novel method of ribozyme-mediated gene identification.
Martin Krueger (2001)
10.1016/1074-5521(95)90182-5
New insights into proteasome function: from archaebacteria to drug development.
A. Goldberg (1995)
Identification and validation of a gene involved in anchorage-independent cell growth control using a library of randomized hairpin ribozymes. Genomics 66:274–283
P. J. Welch (2000)
10.1128/JVI.72.11.8789-8796.1998
The 3′-Untranslated Region of Hepatitis C Virus RNA Enhances Translation from an Internal Ribosomal Entry Site
T. Ito (1998)
10.1073/PNAS.97.15.8566
Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach.
Michael J. Kruger (2000)
10.1182/BLOOD.V91.2.371.371_371_382
The therapeutic potential of ribozymes.
H. James (1998)



This paper is referenced by
10.1111/jvh.12508
Hepatic expression of proteasome subunit alpha type‐6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin‐like modifier, a proviral host gene in hepatitis C virus infection
R. Broering (2016)
10.1128/MCB.01578-08
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
M. López-Lago (2009)
10.1016/J.JHEP.2005.02.046
Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors.
M. Korf (2005)
10.1111/j.1478-3231.2011.02543.x
Hepatitis C viral protein translation: mechanisms and implications in developing antivirals
Brett Hoffman (2011)
10.1016/S0166-3542(03)00174-8
Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents.
V. E. Buckwold (2003)
10.1016/S1477-3627(03)02369-9
Use of random ribozyme libraries for the rapid screening of apoptosis- and metastasis-related genes
L. D. Nelson (2003)
10.1038/sj.onc.1209549
RNA interference-mediated prevention and therapy for hepatocellular carcinoma
P. Romano (2006)
PSMA7 inhibits the tumorigenicity of A549 human lung adenocarcinoma cells
Jia-Yu TanXiang (2012)
10.1016/j.celrep.2013.09.017
mTORC1 targets the translational repressor 4E-BP2, but not S6 kinase 1/2, to regulate neural stem cell self-renewal in vivo.
N. Hartman (2013)
HCV 5′ and 3′UTR: When Translation Meets Replication
S. Shi (2006)
10.1074/jbc.RA118.004383
Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f)
R. Cuesta (2018)
10.1016/S1089-3261(02)00069-7
New therapies on the horizon for hepatitis C: are we close?
R. De Francesco (2003)
10.4314/BAJOPAS.V4I1.16
The Genetic and Molecular Studies of Hepatitis C Virus: A Review
Ld Rogo (2011)
10.1016/S0168-6445(03)00020-2
Ribozymes: recent advances in the development of RNA tools.
E. Puerta-Fernández (2003)
10.1517/14728214.8.1.9
Developments in hepatitis C therapy during 2000 – 2002
F. Poordad (2003)
10.1007/978-3-540-28130-6_10
Potentials of a Ribozyme-Based Gene Discovery System
M. Sano (2006)
10.1073/pnas.202608199
Genomic analysis of the host response to hepatitis C virus infection
A. Su (2002)
10.2217/17460794.1.1.99
Future trends in hepatitis C therapy
M. Cornberg (2006)
10.1039/c0mb00103a
Network based analysis of hepatitis C virus core and NS4B protein interactions.
Lokesh P. Tripathi (2010)
10.1007/s00705-004-0341-8
Polypyrimidine tract-binding protein (PTB) inhibits Hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation, but does not affect HCV replication
J. Tischendorf (2004)
10.1016/J.BBRC.2007.12.092
Upstream open reading frames regulate the expression of the nuclear Wnt13 isoforms.
T. Tang (2008)
10.1385/1-59745-165-7:143
Hammerhead ribozyme-based target discovery.
M. Sano (2007)
10.1016/S0378-1119(03)00774-1
Alternative ways to think about mRNA sequences and proteins that appear to promote internal initiation of translation.
M. Kozak (2003)
10.1016/J.MOLCEL.2004.10.017
20S proteasome differentially alters translation of different mRNAs via the cleavage of eIF4F and eIF3.
James M Baugh (2004)
10.1517/13543776.15.8.1027
Patents and development of HBV and HCV clinical treatment: from 2001 to April 2005
Zhi Chen (2005)
Novel Anti-viral Strategies for Hepatitis C
Q. Pan (2012)
10.1002/cbic.200600180
Bleomycin is a Potent Small‐Molecule Inhibitor of Hepatitis C Virus Replication
B. Rakić (2006)
10.3389/fmicb.2016.00089
Comparative Analysis of Salivary Gland Proteomes of Two Glossina Species that Exhibit Differential Hytrosavirus Pathologies
H. M. Kariithi (2016)
10.1002/DDR.10343
The role of functional genomics in selecting disease targets for antibody‐based therapy
C. Davis (2004)
10.1080/17471060701286559
Study of hepatocytes using RNA interference
S. Niimi (2007)
10.1016/S1471-4892(02)00201-1
Novel technologies for studying virus-host interaction and discovering new drug targets for HCV and HIV.
Hengli Tang (2002)
10.1074/jbc.M700906200
RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation*
Philippe P Roux (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar